Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


ENABLE: an engine for European antibacterial drug discovery and development

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 20, 407-408 (2021)



The authors thank all colleagues and partners involved in ENABLE (Supplementary Table 2), and gratefully acknowledge PMC members and platform leads for providing valuable insights. The authors wish to thank members of the Consortium Management Office, C. Nilsson, E. Bacqué, N. Pearson, R. Neal, F. Deroose, A. Lobell, N. Murillo, L. Löwenau and C. Robijns, for their contributions as well as critical reading of the manuscript. R. Stavenger is acknowledged for his tremendous efforts in helping to set up ENABLE and ensuring its smooth running in the early years. The authors have received support from the IMI Joint Undertaking under grant agreement no. 115583, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme and EFPIA companies’ in-kind contributions.


The views expressed in this article are the views of the authors and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links